Nicholas Wilcken1, Rachel Dear. 1. Department of Medical Oncology, Westmead Hospital, Westmead, NSW 2145, Australia. nicholas_wilcken@wmi.usyd.edu.au
Abstract
AIM: To summarise the findings of all randomised trials comparing chemotherapy regimens for metastatic breast cancer that were reported between 2000 and 2007 inclusive. METHODS: We searched the specialised register of clinical trials maintained by the secretariat of the Cochrane Breast Cancer Group (CBCG) from 2000 to 2007, and abstracts from the American Society of Clinical Oncology (ASCO) annual scientific meeting (2000-2007). RESULTS: Eighty reports of 63 trials were identified as eligible for this review. Whilst over 30% of the trials reported a statistically significant difference in response rate or progression free survival, only 8 trials (13%) reported a difference in overall survival. Thirty percent reported quality of life data. Very few trials examined the critical clinical questions of duration and the relative merits of combination versus sequential single agent chemotherapy. CONCLUDING STATEMENT: There is little evidence from trials reported from 2000 to 2007 that major survival differences exist between many commonly employed chemotherapy regimens.
AIM: To summarise the findings of all randomised trials comparing chemotherapy regimens for metastatic breast cancer that were reported between 2000 and 2007 inclusive. METHODS: We searched the specialised register of clinical trials maintained by the secretariat of the Cochrane Breast Cancer Group (CBCG) from 2000 to 2007, and abstracts from the American Society of Clinical Oncology (ASCO) annual scientific meeting (2000-2007). RESULTS: Eighty reports of 63 trials were identified as eligible for this review. Whilst over 30% of the trials reported a statistically significant difference in response rate or progression free survival, only 8 trials (13%) reported a difference in overall survival. Thirty percent reported quality of life data. Very few trials examined the critical clinical questions of duration and the relative merits of combination versus sequential single agent chemotherapy. CONCLUDING STATEMENT: There is little evidence from trials reported from 2000 to 2007 that major survival differences exist between many commonly employed chemotherapy regimens.
Authors: David M Hyams; Arlene Chan; Celia de Oliveira; Raymond Snyder; Jeferson Vinholes; M William Audeh; Victor M Alencar; Janine Lombard; Bijoyesh Mookerjee; John Xu; Kathryn Brown; Paula Klein Journal: Invest New Drugs Date: 2013-06-26 Impact factor: 3.850
Authors: Dieter Hölzel; Renate Eckel; Ingo Bauerfeind; Bernd Baier; Thomas Beck; Michael Braun; Johannes Ettl; Ulrich Hamann; Nadia Harbeck; Marion Kiechle; Sven Mahner; Christian Schindlbeck; Johann de Waal; Jutta Engel Journal: J Cancer Res Clin Oncol Date: 2016-11-16 Impact factor: 4.553
Authors: Chikako Suzuki; Lennart Blomqvist; Thomas Hatschek; Lena Carlsson; Zakaria Einbeigi; Barbro Linderholm; Birgitta Lindh; Niklas Loman; Martin Malmberg; Samuel Rotstein; Martin Söderberg; Marie Sundqvist; Thomas M Walz; Gunnar Aström; Hirofumi Fujii; Hans Jacobsson; Bengt Glimelius Journal: Med Oncol Date: 2013-01-16 Impact factor: 3.064
Authors: N Tubiana-Mathieu; P Bougnoux; D Becquart; A Chan; P-F Conte; F Majois; M Espie; M Morand; N Vaissiere; G Villanova Journal: Br J Cancer Date: 2009-07-07 Impact factor: 7.640